NewDays Research Is Heading to the World Stage

We're proud to announce that NewDays will be presenting new clinical findings at AD/PD 2026 - one of the most prestigious Alzheimer's and Parkinson's disease conferences in the world.

For too long, people living with cognitive decline have been told there's nothing to do but wait. No real treatment. No real hope. Just watching and wondering.

That era is over.

This month, NewDays co-founder Daniel Kelly will present findings from our first clinical case series at the AD/PD 2026 Annual Conference, the world's leading academic gathering on Alzheimer's and Parkinson's disease research, bringing together thousands of scientists, clinicians, and researchers from across the globe. Being selected to present a poster at AD/PD is a meaningful milestone. It's the first of many peer-reviewed clinical results for our innovative approach to cognitive rehabilitation.

What We Found

The poster covers results for our first cohort of nine patients (eight living with dementia, one with Mild Cognitive Impairment) using NewDays' blended approach: regular telehealth sessions with a licensed clinician, combined with daily AI-guided cognitive exercises through our AI brain trainer, Sunny.

The results, after just 3 to 5 months:

73% of patients showed measurable improvements in cognitive function. Using the Addenbrooke's Cognitive Examination (ACE-III), a gold-standard global cognition measure, scores improved by an average of 3.55 points. Without treatment, patients at this stage would typically be expected to decline by nearly 2 points over the same period. That's a meaningful swing in the right direction.

Better mental health, not just cognition. More than half of patients saw reductions in depressive symptoms. Three out of four showed improvements in anxiety. This matters. Cognitive decline doesn't just affect memory; it affects how people feel about themselves and their lives.

Delayed progression. Dementia patients in our program delayed symptom progression by over a year compared to expected decline curves. A year of staying more yourself. That's what this is about.

Why This Matters

These aren't just numbers on a chart. They represent a fundamental challenge to the idea that nothing can be done.

Cognitive rehabilitation, structured expert-led treatment designed to strengthen and protect the brain, has solid evidence behind it. The problem has always been access. It's expensive, scarce, and hard to sustain. AI changes that equation. By pairing licensed clinicians with a conversational AI that works with patients daily, NewDays delivers the consistency and frequency that good cognitive treatment requires, without the barriers that have kept it out of reach for most people.

This is early data. We're clear-eyed about that. Nine patients, no control group; the science calls for more, and we're building toward it. But the signal is real, and it's pointing in exactly the direction we hoped.

What's Next

Presenting at AD/PD is a beginning, not a finish line. We're designing controlled clinical trials, deepening our understanding of what works for whom, and continuing to build a program that more people can actually access.

The wait-and-see era of cognitive decline is over. NewDays is the proof.

NewDays clinical data peer-reviewed and presented at AD/PD Alzheimer's and Parkinson's Disease Conference, March 2026.
Learn more about AD/PD here: Alzheimer's Disease and Parkinson's Disease, Advances in Science & Therapy | Copenhagen, Denmark | March 17-21, 2026